Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: Results from a randomized, controlled trial

Surgical Infections

Volumn 13, Issue 2, 2012, Pages 102-109

  Qvist, Niels ^a   Warren, Brian ^b   Leister Tebbe, Heidi ^c   Zito, Edward T ^c   Pedersen, Ronald ^c   McGovern, Paul C ^c   Babinchak, Tim ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; METRONIDAZOLE; TIGECYCLINE;

ABDOMINAL INFECTION; ABSCESS; ADULT; ANASTOMOSIS LEAKAGE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEROIDES FRAGILIS; BACTEROIDES INFECTION; CLOSTRIDIUM; CLOSTRIDIUM INFECTION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ERADICATION THERAPY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HEALING IMPAIRMENT; HUMAN; ISCHEMIC COLITIS; KLEBSIELLA; KLEBSIELLA INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PEPTOSTREPTOCOCCUS; PEPTOSTREPTOCOCCUS INFECTION; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS INFECTION; SURGICAL INFECTION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; DRAINAGE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MIDDLE AGED; MINOCYCLINE; TREATMENT OUTCOME;

EID: 84859625873     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2011.048     Document Type: Article

References (24)

1. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009;89:421-437.
2. Inui T, Haridas M, Claridge JA, Malangoni MA. Mortality for intra-abdominal infection is associated with intrinsic risk factors rather than the source of infection. Surgery 2009;146:654-661.
3. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect 2010;11:79-104.
4. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-883.
5. Solomkin J, Zhao YP,Ma EL, et al.Moxifloxacin is non-inferior to combination therapy with ceftriaxone plusmetronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009;34:439-445.
6. Weiss G, Reimnitz P, Hampel B, et al. Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA Study). J Chemother (Florence) 2009;21: 170-180.
7. Namias N, Solomkin JS, Jensen EH, et al. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect 2007;8:15-28.
8. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillintazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006;244: 204-211.
9. Dela Pena AS, Asperger W, Kockerling F, et al. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 2006;10:567-574.
10. Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactamadministered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50:3556-3561.
11. Giamarellou H, Poulakou G. Multidrug-resistant gramnegative infections: What are the treatment options? Drugs 2009;69:1879-1901.
12. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006;43:518-524.
13. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56: 470-480.
14. Peterson LR. A review of tigecycline: The first glycylcycline. Int J Antimicrob Agents 2008;32(Suppl 4):S215-S222.
15. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):S315-S332.
16. Revising the Declaration of Helsinki. BullMed Ethics 2000:9-11.
17. Mehrotra DV, Railkar R. Minimum risk weights for comparing treatments in stratified binomial trials. Stat Med 2000;19:811-825.
18. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 2005;5:88.
19. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surgery 2005;3:35-47.
20. Towfigh S, Pasternak J, Poirier A, et al. A multicentre, openlabel, randomised comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalised subjects with complicated intra-abdominal infections. ClinMicrobiol InfectNov 20, 2009; e-pub ahead of print.
21. Kollef MH. Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin Infect Dis 2006;43(Suppl 2):S82-S88.
22. McNulty CA, Richards J, Livermore DM, et al. Clinical relevance of laboratory-reported antibiotic resistance in acute uncomplicated urinary tract infection in primary care. J Antimicrob Chemother 2006;58:1000-1008.
23. Dupont H. The empiric treatment of nosocomial intraabdominal infections. Int J Infect Dis 2007;11(Suppl 1):S1-S6.
24. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: Getting it right the first time. Drugs 2003;63:2157-2168.